These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth. Di Malta C; Siciliano D; Calcagni A; Monfregola J; Punzi S; Pastore N; Eastes AN; Davis O; De Cegli R; Zampelli A; Di Giovannantonio LG; Nusco E; Platt N; Guida A; Ogmundsdottir MH; Lanfrancone L; Perera RM; Zoncu R; Pelicci PG; Settembre C; Ballabio A Science; 2017 Jun; 356(6343):1188-1192. PubMed ID: 28619945 [TBL] [Abstract][Full Text] [Related]
24. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Ho WS; Wang H; Maggio D; Kovach JS; Zhang Q; Song Q; Marincola FM; Heiss JD; Gilbert MR; Lu R; Zhuang Z Nat Commun; 2018 May; 9(1):2126. PubMed ID: 29844427 [TBL] [Abstract][Full Text] [Related]
25. Combinatorial immunotherapy induces tumor-infiltrating CD8 Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555 [TBL] [Abstract][Full Text] [Related]
27. The E3 ubiquitin ligase Peli1 regulates the metabolic actions of mTORC1 to suppress antitumor T cell responses. Ko CJ; Zhang L; Jie Z; Zhu L; Zhou X; Xie X; Gao T; Yang JY; Cheng X; Sun SC EMBO J; 2021 Jan; 40(2):e104532. PubMed ID: 33215753 [TBL] [Abstract][Full Text] [Related]
28. Tet2 Inactivation Enhances the Antitumor Activity of Tumor-Infiltrating Lymphocytes. Lee M; Li J; Li J; Fang S; Zhang J; Vo ATT; Han W; Zeng H; Isgandarova S; Martinez-Moczygemba M; Zhou Y; Sun D; Huang Y Cancer Res; 2021 Apr; 81(8):1965-1976. PubMed ID: 33589517 [TBL] [Abstract][Full Text] [Related]
29. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors. Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902 [TBL] [Abstract][Full Text] [Related]
30. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts. Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263 [TBL] [Abstract][Full Text] [Related]
31. Developing a comprehensive solution aimed to disrupt LARS1/RagD protein-protein interaction. Raevsky A; Kovalenko O; Bulgakov E; Sharifi M; Volochnyuk D; Tukalo M J Biomol Struct Dyn; 2024; 42(2):747-758. PubMed ID: 36995308 [TBL] [Abstract][Full Text] [Related]
33. Leucine-induced localization of Leucyl-tRNA synthetase in lysosome membrane. Choi H; Son JB; Kang J; Kwon J; Kim JH; Jung M; Kim SK; Kim S; Mun JY Biochem Biophys Res Commun; 2017 Nov; 493(2):1129-1135. PubMed ID: 28882589 [TBL] [Abstract][Full Text] [Related]
34. Structure-based modification of pyrazolone derivatives to inhibit mTORC1 by targeting the leucyl-tRNA synthetase-RagD interaction. Kim JH; Jung K; Lee C; Song D; Kim K; Yoo HC; Park SJ; Kang JS; Lee KR; Kim S; Han JM; Han G Bioorg Chem; 2021 Jul; 112():104907. PubMed ID: 33979735 [TBL] [Abstract][Full Text] [Related]
38. Differential regulation of mTORC1 activation by leucine and β-hydroxy-β-methylbutyrate in skeletal muscle of neonatal pigs. Suryawan A; Rudar M; Fiorotto ML; Davis TA J Appl Physiol (1985); 2020 Feb; 128(2):286-295. PubMed ID: 31944890 [TBL] [Abstract][Full Text] [Related]
39. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609 [TBL] [Abstract][Full Text] [Related]
40. Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity. Myers DR; Abram CL; Wildes D; Belwafa A; Welsh AMN; Schulze CJ; Choy TJ; Nguyen T; Omaque N; Hu Y; Singh M; Hansen R; Goldsmith MA; Quintana E; Smith JAM; Lowell CA Front Immunol; 2020; 11():576310. PubMed ID: 33133093 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]